Dr Harrison was supportive of the coordinated national start date. Read more about Dr Harrison was supportive of the coordinated national start date.
A draft circular on changes to blood handling charges circulated to recipients in the Department of Health stated: "Ministers have agreed that screening for HCV should be introduced as a public health measure. A starting date of 1 July has been set". Read more about A draft circular on changes to blood handling charges circulated to recipients in the Department of Health stated: "Ministers have agreed that screening for HCV should be introduced as a public health measure. A starting date of 1 July has been set".
The Chief Medical Officer endorsed the recommendation that routine screening should be introduced as a public health measure. Read more about The Chief Medical Officer endorsed the recommendation that routine screening should be introduced as a public health measure.
Dr Barbara's written evidence to this Inquiry was that the second-round comparative evaluation of test kits needed to be completed and to gain more experience in confirmatory assays before reliable and more accurate and specific testing could begin with workable methods for determining the infection status of the donor. Read more about Dr Barbara's written evidence to this Inquiry was that the second-round comparative evaluation of test kits needed to be completed and to gain more experience in confirmatory assays before reliable and more accurate and specific testing could begin with workable methods for determining the infection status of the donor.
Dr Gunson noted that Chiron had announced that it was working on a recombinant immunoblot assay confirmatory test, but that it was not yet available. Read more about Dr Gunson noted that Chiron had announced that it was working on a recombinant immunoblot assay confirmatory test, but that it was not yet available.
In his written statement to the Inquiry, Dr Lloyd commented that the RIBA II assay "appeared to substantially remove the issue of lack of specificity. Once the RIBA II test was available, the lack of specificity with the first-generation test would have been much more manageable". Read more about In his written statement to the Inquiry, Dr Lloyd commented that the RIBA II assay "appeared to substantially remove the issue of lack of specificity. Once the RIBA II test was available, the lack of specificity with the first-generation test would have been much more manageable".
Dr Lloyd's evidence to the Inquiry was that running a trial on the more effective second-generation tests instead of starting general screening was illogical. Read more about Dr Lloyd's evidence to the Inquiry was that running a trial on the more effective second-generation tests instead of starting general screening was illogical.
Dr Lloyd described the "extended test" as a "face saving exercise". Read more about Dr Lloyd described the "extended test" as a "face saving exercise".
In his written statement to the Inquiry, Dr Lloyd stated that had he seen the ACVSB meeting notes of 21 November 1990, he might have considered starting testing at Newcastle RTC earlier than they did. Read more about In his written statement to the Inquiry, Dr Lloyd stated that had he seen the ACVSB meeting notes of 21 November 1990, he might have considered starting testing at Newcastle RTC earlier than they did.
Dr Perry identified a number of shortcomings in the decision-making process with regard to the introduction of routine testing. Read more about Dr Perry identified a number of shortcomings in the decision-making process with regard to the introduction of routine testing.